U.S. markets closed

  • S&P 500

    4,246.59
    -8.56 (-0.20%)
     

  • Dow 30

    34,299.33
    -94.42 (-0.27%)
     

  • Nasdaq

    14,072.86
    -101.29 (-0.71%)
     

  • Russell 2000

    2,320.07
    -6.07 (-0.26%)
     

  • Crude Oil

    72.48
    +1.60 (+2.26%)
     

  • Gold

    1,860.30
    -5.60 (-0.30%)
     

  • Silver

    27.79
    -0.25 (-0.89%)
     

  • EUR/USD

    1.2132
    +0.0009 (+0.07%)
     

  • 10-Yr Bond

    1.4990
    -0.0020 (-0.13%)
     

  • GBP/USD

    1.4081
    -0.0026 (-0.19%)
     

  • USD/JPY

    110.0410
    -0.0200 (-0.02%)
     

  • BTC-USD

    40,063.68
    -46.01 (-0.11%)
     

  • CMC Crypto 200

    996.53
    -14.08 (-1.39%)
     

  • FTSE 100

    7,172.48
    +25.80 (+0.36%)
     

  • Nikkei 225

    29,441.30
    +279.50 (+0.96%)
     
Webinar:

Biden's budget and policy priorities

Yahoo Finance and The Bipartisan Policy Center on the budget and what may come on taxes, infrastructure, and more on 6/16 at 10 a.m. ET

Options Traders Speculate on OCGN After Vaccine Update

  • Oops!
    Something went wrong.
    Please try again later.
Jake Scott
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

The shares of biopharmaceutical concern Ocugen Inc (NASDAQ:OCGN) are surging this afternoon, last seen up 7.2% to trade at $6.56. The positive price action comes after the company announced it is is partnering with Jubilant HollisterStier to manufacture its Covid-19 vaccine candidate Covaxin™ for use in the U.S. as well as Canada. Though the vaccine has not yet been approved, options traders are responding to the news with enthusiasm.

So far today, 91,000 calls and 27,000 puts have crossed the tape, which is double what is typically seen at this point. Most popular by far is the June 7 call, followed by the 7.5 call in the same series, with new positions being opened at both. This indicates traders are speculating on additional upside for OCGN by the time contracts expire on Friday.

Analysts are bearish on Ocugen stock, with three of the four in coverage recommending a tepid "hold." In other words, a shift in sentiment could propel the equity higher. What's more, OCGN's 12-month consensus price target of $5.38 is a 17.5% discount to current levels, leaving plenty of room for upgrades in the near future.

On the charts, Ocugen stock is far from being the powerhouse it once was when the company first went public in 2015, trading around the $600 level. After meddling below the $1 mark since November 2019, though, the equity finally broke above that level last December. It has been a a volatile run on the charts for OCGN since then, but the stock still boasts a jaw-dropping 2,293.1% year-over-year rise.

OCGN Chart June 15
OCGN Chart June 15

Recommended Stories

  • Ocugen's stock is up 14% after announcing manufacturing partner for experimental COVID-19 shot

    Shares of Ocugen Inc. gained 14.3% in premarket trading on Tuesday after the company said it picked Jubilant HollisterStier, a privately held pharmaceutical contract manufacturer, to produce its still-investigational COVID-19 vaccine for the U.S. and Canada. The vaccine is not authorized or approved in either country at this time. Ocugen's stock is up 239.4% so far this year, while the broader S&P 500 has gained 13.3%.

  • Ocugen Stock Crashes: What Should Investors Do Now?

    Just a few days ago, Ocugen (NASDAQ: OCGN) was flying high with shares up more than 460% year to date. Investors were hopeful that the small drugmaker would be able to win U.S. Emergency Use Authorization (EUA) for Covaxin, the COVID-19 vaccine developed by Ocugen's partner, Bharat Biotech. On June 10, though, Ocugen announced that the U.S. Food and Drug Administration (FDA) had effectively shut the door on an EUA filing.

  • Semiconductor Companies: Where Are They In The Chip Cycle?

    The chip industry has seen tremendous growth in recent years, but hit a soft patch in late 2018. What you need to know about this cyclical industry.

  • Is Micron Stock A Buy As Memory-Chip Market Recovers?

    Micron Technology stock has risen recently on signs of improving memory-chip sales. Here is what the fundamentals and technical analysis say about buying MU stock right now.

  • UPDATE 1-Novavax COVID-19 vaccine more than 90% effective in U.S. trial

    Novavax Inc on Monday said its COVID-19 vaccine was more than 90% effective, including against a variety of concerning variants of the coronavirus in a large, late-stage U.S.-based clinical trial. The study of nearly 30,000 volunteers in the United States and Mexico puts Novavax on track to file for emergency authorization in the United States and elsewhere in the third quarter of 2021, the company said. The protein-based vaccine was more than 93% effective against the more easily transmissible predominant coronavirus variants that have caused concern among scientists and public health officials, Novavax said.

  • Docusign Receives Composite Rating Upgrade During Consolidation

    The IBD SmartSelect Composite Rating for Docusign increased from 91 to 96 Monday. The new score means the company is now outperforming 96% of all stocks in terms of the most important fundamental and technical stock-picking criteria. Docusign is currently forming a consolidation, with a 290.33 buy point.

  • Uber, Lyft drivers say new California law isn’t solving health-care needs

    California lawmakers join drivers' push for action, including at the federal level, by urging passage of the PRO Act and for the NLRB to classify gig workers as employees.

  • BlackBerry Investors Urged to Oppose Watsa on Executive Pay

    (Bloomberg) -- A shareholder advisory firm urged BlackBerry Ltd. investors to vote against Prem Watsa as lead director, arguing that he should be held accountable for an executive compensation plan that isn’t in shareholders’ interests.Glass Lewis & Co. said the company “has been deficient in aligning pay with performance for each of the last three fiscal years,” and that Watsa, who also has led the board’s compensation committee since late 2013, shouldn’t keep his role. Watsa is one of Canada’s

  • Is PDS Biotechnology Corporation (PDSB) A Good Stock To Buy?

    Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors’ consensus returns have been exceptional. In the following paragraphs, we find out […]

  • Will This News Stop Ocugen Shares in Their Tracks?

    The company signed a deal with Bharat Biotech to co-commercialize Bharat's near-to-market coronavirus vaccine candidate in the U.S. In recent days, the companies expanded the deal to include Canada as well. From the start of the year to a peak in February, Ocugen shares rose more than 760%. Ocugen said that it won't pursue Emergency Use Authorization (EUA) in the U.S. for its vaccine candidate -- known as Covaxin.

  • Why COVID Vaccine Stocks Dynavax, Novavax, and Vaxart Are Sinking Today

    Dynavax Technologies (NASDAQ: DVAX) stock was down 6.3% as of 11:26 a.m. EDT, while shares of Novavax (NASDAQ: NVAX) and Vaxart (NASDAQ: VXRT) were falling 7.8% and 10.6%, respectively. The declines for the biotech stocks appear to merely be run-of-the-mill volatility on a day when the overall stock market was down. Sales of its Heplisav-B hepatitis B vaccine were negatively impacted by the COVID-19 pandemic.

  • 10 Best Steel Stocks to Buy Amid Upcoming Infrastructure, Construction Boom

    In this article we will take a look at the 10 best steel stocks to buy amid upcoming infrastructure, construction boom. You can skip our detailed analysis of these companies, and go directly to the 5 Best Steel Stocks to Buy Amid Upcoming Infrastructure, Construction Boom. Steel prices are soaring amid a rising demand as […]

  • Should Investors Buy Just Eat Takeaway After It Devours Grubhub?

    Just Eat Takeaway's (OTC: GRUB) $7.3 billion takeover of Grubhub, which was announced a year ago, finally closed on June 15. Grubhub's investors received 0.671 shares of the new American depositary receipts for each of their original shares, and the merged company will become one of the world's largest third-party food delivery platforms outside of China. Grubhub's investors might be wondering if they should sell their new shares or put some faith in the new company.

  • First Look: Solid Power, a Ford-Backed QuantumScape Rival, Will Go Public via SPAC

    Many investors have been overwhelmed by the number of SPAC deals in the electric-vehicle space over the last year, and some have soured on the space now that a couple of last year's darlings have turned out to be, well, less than they seemed. Colorado-based Solid Power, founded in 2012, is one of several companies working to develop so-called solid-state batteries, which omit the liquid electrolyte used in the lithium-ion batteries that power most electric vehicles today.

  • Hedge Funds Keep Buying Roku, Inc. (ROKU)

    The Insider Monkey team has completed processing the quarterly 13F filings for the March quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as […]

  • Why Nikola Stock Dropped Tuesday -- Though Maybe It Shouldn't Have

    As of 11:50 a.m. EDT, Nikola shares were down 7.6%. There are two pieces of news today that are related to the use of hydrogen in transportation, which Nikola is counting on for its long-term success. First, in what could be potentially considered direct competition for Nikola, the Jaguar Land Rover automotive brand announced it is developing a hydrogen fuel cell electric vehicle (FCEV) based on its new Land Rover Defender sport utility vehicle.

  • 3 Inflation-Resistant Stocks to Buy Right Now

    Investors might want an inflation hedge, and these three companies have additional reasons to own them.

  • Oracle Earnings Blow Past Guidance, but Stock Slips as Investors Take Profits

    Oracle stock is trading modestly lower after hours as some investors take profits after a nearly 30% rally in the shares since mid-March.

  • Why Nio Stock is Trading Higher?

    The Chinese Electric Vehicle manufacturer Nio Inc. (NIO) has witnessed steady gains in its stock price over the past month. The stock is up around 37% and closed 2% higher on June 14 at $46.55. The Good News? Nio has had a series of good news coming its way, with the latest being that construction of its second factory has begun, and the plant is expected to start manufacturing in the third quarter of 2022. The news was confirmed by CEO William Li at a recent event in China. (See Nio stock analy

  •  Hindenburg alleges 'black market operations' against DKNG

    Daniel Adam Loop Capital Markets Analyst joins the Yahoo Finance Live panel to discuss the latest as Hindenburg Research reveals short position in DraftKings.